Skip to main content
MSF logo
  • Media room
  • Contact
  • msf.org
  • MSF Access
    • About MSF Access
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Our work
    • Diabetes
    • Drug-resistant infections
    • Hypertension
    • Patents and intellectual property
      • Pandemic prevention, preparedness and response
      • The Patent Oppositions Database
    • Research and development
      • Spotlight on: the Big Pharma double-dip
      • Transparency Matters: Clinical Trials Costs
    • Tuberculosis
    • Vaccines
    • Other work
      • COVID-19
      • Hepatitis C
      • HIV/AIDS
      • Tropical and neglected diseases
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Get involved
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • A Fair Shot
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    • Recent campaigns
      • Time for $5
      • No Patents in a Pandemic
      • Share the Tech - Save Lives
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Resources
    • Press releases
    • Statements
    • Letters
    • Opinion articles
    • Feature stories
    • Interviews
    • Blog
    • Newsletters
    • Publications
    • Research articles
    • Topic overview pages
    • Videos
    • Photo stories
    • Infographics
    • Events
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Media room
  • Contact
  • msf.org
  • MSF Access
    • About MSF Access
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Our work
    • Diabetes
    • Drug-resistant infections
    • Hypertension
    • Patents and intellectual property
      • Pandemic prevention, preparedness and response
      • The Patent Oppositions Database
    • Research and development
      • Spotlight on: the Big Pharma double-dip
      • Transparency Matters: Clinical Trials Costs
    • Tuberculosis
    • Vaccines
    • Other work
      • COVID-19
      • Hepatitis C
      • HIV/AIDS
      • Tropical and neglected diseases
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Get involved
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • A Fair Shot
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    • Recent campaigns
      • Time for $5
      • No Patents in a Pandemic
      • Share the Tech - Save Lives
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Resources
    • Press releases
    • Statements
    • Letters
    • Opinion articles
    • Feature stories
    • Interviews
    • Blog
    • Newsletters
    • Publications
    • Research articles
    • Topic overview pages
    • Videos
    • Photo stories
    • Infographics
    • Events
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
Medicines shouldn’t be a luxury Take action
Get involved
Our campaigns

Latest Press Releases

Latest Press Releases

Sinethemba takes her daily regimen for XDR-TB at 10am each day. She also takes two additional delamanid tablets at night. She is 16 years old, lives with her grandmother, Vuyisiwa Madubela, and four other family members in a two-bedroomed home in Zone C29, Khayelitsha, Western Cape, South Africa. Her grandmother’s determination and love, combined with receiving a six-month trial of one the newest DR-TB drugs on the market likely saved her life this year. Photograph by Sydelle Willow Smith
Press release
Press release |
18 June 2018
Tuberculosis
South Africa

South Africa: A new revolution in TB treatment as the injection falls

The International General Assembly (IGA), June 2013, Brussels. The IGA is the highest governance body within MSF. It safeguards our medical humanitarian mission and provides general and strategic orientations across the movement. The assembly is composed of two representatives from each MSF association and the MSF International President. Each representative has a single independent vote. Photograph by Bruno De Cock
Press release
Press release |
04 June 2018

MSF Access Campaign names new Head of Policy

A woman dances during a Stop Stock Outs Project activist meeting in Soshanguve, a township outside of Pretoria on April 16, 2015. As a grassroots project, SSP regularly organizes training for people living with HIV in order to equip them on the know how to monitor and report drug shortages. Photograph by Stefan Heunis
Press release
Press release |
31 May 2018
Intellectual property and trade
South Africa

South Africa takes landmark step for access to medicines

Mbandaka hospital in Equateur province, DRC 2018. MSF staff Teams treating patients in the isolation areas in Mbandaka hospital. MSF teams are currently in the Mbandaka and Bikoro areas and are putting in place two Ebola Treatment Centres of 20 beds each. Photograph by Louise Annaud Photograph by Louise Annaud
Press release
Press release |
29 May 2018
Tropical & neglected diseases
Democratic Republic of the Congo

Democratic Republic of Congo: MSF starts Ebola vaccination targeting remote communities

4 min
Control of Neglected Tropical Diseases With Different Antivenoms
Press release
Press release |
24 May 2018
Tropical & neglected diseases
G20

Governments finally take important step to tackle global snakebite crisis

what-does-the-msf-access-campaign-do Photograph by Todd Brown
Press release
Press release |
14 May 2018
Research and development

MSF responds to President Trump's speech on drug pricing

3 min
Photograph by Siddharth Singh Photograph by Siddharth Singh
Press release
Press release |
27 April 2018
Intellectual property and trade

USTR Priority Watch List calls out countries for protecting public health

4 min
EU-India FTA Photograph by Siddarth Singh
Press release
Press release |
10 April 2018
Intellectual property and trade

MSF statement on resumption of EU-India FTA negotiations

  • Load More
Navigate
  • About MSF Access
  • Contact us
  • Get involved
  • Our work
  • Resources
  • Search
Get updates
  • Sign up for our newsletter
  • Privacy & data protection information
Contact

MSF Access
Médecins Sans Frontières
140 Route de Ferney
1202 Geneva, Switzerland
Phone:+41 22 849 8484
E-mail: [email protected]

Follow us

  • X
  • Facebook
  • YouTube
  • Medium
Medicines Shouldn't Be A Luxury